Analysis of gene polymorphisms in the regulatory region of MCP-1, RANTES, and CCR5 in liver transplant recipients

Journal of Clinical Immunology

Volumn 22, Issue 6, 2002, Pages 381-385

  Schröppel, Bernd ^a   Fischereder, Michael ^b   Lin, Marvin ^c   Marder, Brad ^c   Schiano, Tom ^c   Krämer, Bernhard K ^b   Murphy, Barbara ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c NONE

Author keywords

CCR5; Graft survival; Liver transplantation; MCP 1; RANTES; Rejection

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CHEMOKINE RECEPTOR CCR5; CYCLOSPORIN A; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RANTES; STEROID; TACROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; PHYSIOLOGY; REGULATORY SEQUENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; TREATMENT OUTCOME;

ADULT; CHEMOKINE CCL2; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RANTES; RECEPTORS, CCR5; REGULATORY SEQUENCES, NUCLEIC ACID; RISK FACTORS; TREATMENT OUTCOME;

EID: 0036844983     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020612500935     Document Type: Article

References (20)

1. Akalin E, Murphy B. Gene polymorphisms and transplantation. Curr Opin Immunol 13:572-576, 2001
2. Fischereder M, Luckow B, Hocher B, Wuthrich RP, Rothenpieler U, Schneeberger H, Panzer U, Stahl RA, Hauser IA, Budde K, Neumayer H, Krämer BK, Land W, Schlöndorff D: CC chemokine receptor 5 and renal-transplant survival. Lancet 357:1758-1761, 2001
3. Nelson PJ, Krensky AM: Chemokines, chemokine receptors and allograft rejection. Immunity 14:377-386, 2001
4. Grandaliano G, Gesualdo L, Ranieri E, Monno R, Stallone G, Schena FP: Monocyte chemotactic peptide-1 expression and monocyte infiltration in acute renal transplant rejection. Transplantation 63:414-420, 1997
5. Segerer S, Cui Y, Eimer F, Goodpaster T, Hudkins KL, Mack M, Cartron JP, Colin Y, Schlöndorff D, Alpers CE: Expression of chemokines and chemokine receptors during human renal transplant rejection. Am J Kidney Dis 37:518-531, 2001
6. Gröne HJ, Weber C, Weber KS, Gröne EF, Rabelink T, Klier CM, Wells TN, Proudfoot AE, Schlöndorff D, Nelson PJ: Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: Blocking monocyte arrest and recruitment. FASEB J 13:1371-1383, 1999
7. Song E, Zou H, Yao Y, Proudfoot A, Antus B, Liu S, Jens L, Heemann U: Early application of Met-RANTES ameliorates chronic allograft nephropathy. Kidney Int 61:676-685, 2002
8. Goddard S, Williams A, Morland C, Qin S, Gladue R, Hubscher SG, Adams DH: Differential expression of chemokines and chemokine receptors shapes the inflammatory response in rejecting human liver transplants. Transplantation 72:1957-1967, 2001
9. Schenk M, Zipfel A, Schulz C, Becket HD, Viebahn R: RANTES in the postoperative course after liver transplantation. Transpl Int 13 Suppl 1:S147-149, 2000
10. Rovin BH, Lu L, Saxena R: A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 259:344-348, 1999
11. Liu H, Chao D, Nakayama EE, Taguchi H, Goto M, Xin X, Takamatsu JK, Saito H, Ishikawa Y, Akaza T, Juji T, Takebe Y, Ohishi T, Fukutake K, Maruyama Y, Yashiki S, Sonoda S, Nakamura T, Nagai Y, Iwamoto A, Shioda T: Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci USA 96:4581-4585, 1999
12. Shieh B, Liau YE, Hsieh PS, Yan YP, Wang ST, Li C: Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4. Int Immunol 12:1311-1318, 2000
13. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM: CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 352:866-870, 1998
14. al Sharif F, Ollier WER, Hajeer AH: A rare polymorphism at position -28 in the human RANTES promoter. Eur J Immunogenet 26:373-374, 1999
15. Szalai C, Duba J, Prohaszka Z, Kalina A, Szabo T, Nagy B, Horvath L, Csaszar A: Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 158:233-239, 2001
16. Gao W, Faia KL, Csizmadia V, Smiley ST, Soler D, King JA, Danoff TM, Hancock WW: Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 72:1199-205, 2001
17. Abdi R, Huong TT, Sahagun-Ruiz A, Murphy PM, Brenner BM, Milford EL, McDermott DH: Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 13:754-758, 2002
18. Schröppel B, Fischereder M, Ashkar R, Lin M, Krämer BK, Marder B, Schiano T, Murphy B: The impact of polymorphisms in chemokine and chemokine receptors on outcomes in liver transplantation. Am J Transplant, in press.
19. Moore SB: Is HLA matching beneficial in liver transplantation? Liver Transpl 7:774-776, 2001
20. Boring L, Gosling J, Cleary M, Charo IF: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394:894-897, 1998